The Centers for Disease Control and Prevention is providing new grant funding for a hepatitis B vaccine trial in Guinea-Bissau that had previously been suspended and that experts say is unethical. The development was included in MedPage Today's weekly public health policy roundup, which cited a Rolling Stone report.
The roundup does not provide additional details about the trial's design, the reasons for its earlier suspension, or the specific ethical objections raised by experts. It also does not indicate whether the CDC has responded to the criticism.
This is one of several public health policy items in the roundup, but the other items — including the withdrawal of an NIAID nominee and a measles outbreak response — are not connected to the vaccine trial in the source.